

Leuven, 20 December 2018

Request for proposal of external statutory Auditor mandate

Offerteaanvraag voor mandaat externe statutaire Commissaris

Demande de proposition pour mandat de Commissaire statutaire externe

Oxurion's external statutory audit mandate currently held by BDO Bedrijfsrevisoren comes to an end at the next annual general meeting of shareholders on May 7, 2019. The general meeting will decide on either the renewal of the mandate of the current external statutory auditor or the appointment of a new external statutory auditor. Any interested statutory auditor (bedrijfsrevisor/reviseur d'entreprises) can express his interest by sending an email to Oxurion's CFO, Dominique Vanfleteren (Dominique.Vanfleteren@oxurion.com) before 19 January 2019. The deadline for the external audit services proposal is fixed on 15 February 2019.

Het externe mandaat van statutaire commissaris voor Oxurion, dat uitgevoerd wordt door BDO Bedrijfsrevisoren, beëindigd op de volgende jaarlijkse algemene vergadering van aandeelhouders, gehouden op 7 mei 2019. De algemene vergadering zal beslissen of het mandaat van de huidige externe statutaire commissaris hernieuwd wordt, of dat een nieuwe externe commissaris benoemd wordt. Iedere geïnteresseerde bedrijfsrevisor mag zijn/haar interesse per e-mail bekend maken bij Oxurion's CFO, Dominique Vanfleteren (Dominique.vanfleteren@oxurion.com) vóór 19 januari 2019. De uiterste datum voor een voorstel van externe controle diensten is vastgelegd op 15 februari 2019.

Le mandat du commissaire statutaire actuel d'Oxurion, BDO Reviseurs d'Entreprises, vient à échéance à l'issue de la prochaine assemblée générale annuelle des actionnaires, le 7 mai 2019. L'assemblée se prononcera sur le renouvellement du mandat du commissaire actuel ou sur la nomination d'un nouveau commissaire. Chaque réviseur peut manifester son intérêt pour le mandat en envoyant un email au CFO d'Oxurion, Dominique Vanfleteren (Dominique.Vanfleteren@oxurion.com) avant le 19 janvier 2019. Le délai pour la transmission d'une offre de services se terminera le 15 février 2019.

END

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company focused on transforming treatments to preserve vision in patients with diseases affecting the back of the eye. The company is currently developing a competitive pipeline of disease-modifying drug candidates for diabetic eye disease, a leading cause of blindness of people of working age worldwide.

Oxurion's most advanced drug candidate is THR-317, a PIGF inhibitor for the treatment of diabetic macular edema (DME), which is currently in a Phase 2 study in combination with Lucentis[®]. THR-317 is also being evaluated in a Phase 2 study for the treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1), a rare retinal disease that affects the macula and can lead to vision loss.

Oxurion has two further pipeline candidates, THR-149, a plasma kallikrein inhibitor being developed for the treatment of DME; and THR-687, a pan-RGD integrin antagonist in development for the treatment of diabetic retinopathy and DME. Both THR-149 and THR-687 are in Phase 1 clinical studies.

Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR.

More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.